Fenwick & West represented Solta Medical, Inc. (NASDAQ: SLTM), designer, developer, manufacturer and marketer of energy-based medical device systems for aesthetic applications, in its acquisition by Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX), a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology, and branded generics. Valeant will acquire all of the outstanding common stock of Solta Medical for $2.92 per share in cash, which represents a 40% premium to Solta Medical’s closing price on December 13, 2013, the last trading day prior to the announcement, or an approximate aggregate value of $250 million. The transaction is expected to close in the first quarter of 2014.

The Fenwick transaction team included corporate partners Daniel Winnike and Kris Withrow; executive compensation and employee benefits partner Blake Martell; intellectual property and antitrust partner Mark Ostrau; and tax partner Ronald Schrotenboer. The deal team also included corporate associates Ken Myers, Niki Fang, Scott Behar, Kristin O’Hanlon and Julia Forbess; executive compensation and employee benefits associate Adriana Sherwood; technology transactions associate Claire O’Callaghan; and foreign lawyer clerk Guilherme Potenza.

More information about Solta Medical’s acquisition by Valeant Pharmaceuticals is available through the announcement on Solta Medical’s website.

Login

Don’t have an account yet?

Register